P2.10. Real-World Outcome of Metastatic ALK-Positive Non-Small Cell Lung Cancer Treated with Tyrosine Kinase Inhibitors - PDF(Abstract)
Back to course
Pdf Summary
Asset Subtitle
Per Hydbring
Meta Tag
Speaker Per Hydbring
Topic Metastatic NSCLC: Targeted Therapy - FUSIONS
metastatic ALK-positive non-small cell lung cancer
tyrosine kinase inhibitors
Swedish patients
ALK TKI treatment
resistance mechanisms
adenocarcinoma histology
ALK fusion variants
progression-free survival
second-generation ALK TKIs
Powered By